Month: April 2023

Devin K. Schaffer, J.D., M.B.A, General Counsel, GeneDx GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Devin K. Schaffer has been appointed General Counsel, effective April 24, 2023. As a member of the executive leadership team, Devin will report directly to Katherine Stueland, President and CEO, and will be responsible for all legal, compliance, and regulatory activities for GeneDx.STAMFORD, Conn., April 03, 2023 (GLOBE NEWSWIRE) — GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Devin K. Schaffer has been appointed General Counsel, effective April 24, 2023. As a member of the executive leadership team, Devin will report directly to Katherine Stueland, President...

ROCHESTER, N.Y., April 03, 2023 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, announced that on March 30, 2023 the company closed the private placement of an aggregate of 4,975,608 shares of its common stock at a purchase price of $0.41 per share for aggregate gross proceeds of $2.04 million. No warrants, derivatives, or financial covenants are associated with the private placement. Participants in the private placement included entities controlled by Dr. Maurice Zauderer, President and CEO of Vaccinex and a member of the board of directors, and Albert D. Friedberg, Chairman of Vaccinex’s board of directors. These investors purchased an aggregate...

–Fourth Quarter Sales of $12.3 Million, Up 285%, and Gross Profit of $4.0M Up 321%, over Q4 2021 -Full Year Sales of $29.3 Million, Up 120%, and Gross Profit of $10.2 Million Up 93%; over 2021 HOLLYWOOD, FL, April 03, 2023 (GLOBE NEWSWIRE) — Healthier Choices Management Corp. (OTC Pink: HCMC) today announced financial results for the fourth quarter and the twelve-months ended December 31, 2022. Fourth Quarter 2022 Results and Recent Highlights:Net sales from operations for the three-month period ended December 31, 2022, amounted to $12.3 million, compared to $3.2 million, an approximately $9.1 million and 285% increase versus the same period in 2021. Gross Profit from Operations increased by approximately $3.1 million for the three-month period ended December 31, 2022, amounting to $4.0 million, compared to $1.0 million...

ATHENS, Greece, April 03, 2023 (GLOBE NEWSWIRE) — TOP Ships Inc. (the “Company”), an international owner and operator of modern, fuel efficient “ECO” tanker vessels, announced today that its annual report on Form 20-F for the year ended December 31, 2022 (the “Annual Report”) has been filed with the U.S. Securities and Exchange Commission (the “Commission”). The Annual Report may be accessed through the Company’s website, www.topships.org, or on the website of the Commission, www.sec.gov. About TOP Ships Inc. TOP Ships Inc. is an international ship-owning company.For more information about TOP Ships Inc., visit its website: www.topships.org. Forward-Looking Statements Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe...

Carlsbad, CA, April 03, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has entered into definitive agreements with institutional investors for the purchase of 2,272,723 shares of common stock (or certain pre-funded warrants in lieu thereof) in a registered direct offering and concurrent private placement, at a purchase price per share of $2.64. Certain investors will receive a portion of their investment in unregistered shares or unregistered pre-funded warrants in the private placement in lieu of registered common stock. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the registered direct and private placement offerings. Palisade Bio intends to use...